Alpha synuclein reveals complexity behind Alzheimer’s and Parkinson’s diagnosis Emerging data shows alpha synuclein may be present in the majority of neurodegenerative disease cases, reshaping how clinicians understand dementia and Parkinson’s.

https://www.drugdiscoverynews.com/alpha-synuclein-reveals-complexity-behind-alzheimer-s-and-parkinson-s-diagnosis-17131 Neurodegenerative diseases are among the most complex and devastating conditions in medicine. They progress slowly, often silently, for years or even decades before symptoms become obvious — and by the time a patient reaches a specialist’s office, substantial and irreversible neuronal damage has already occurred. Today, more than 55 million people worldwide live with dementia, a figure projected to climb to roughly 140 million by 2050, with an estimated global cost of $1 trillion annually.